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Abstract 
Introduction: Staphylococcus pseudintermedius, a bacterium considered part of the 
normal flora in dogs, poses a serious threat to the canine health system because it carries 
a large assortment of pathogenicity and virulence genes, which allow it to be capable of 
developing multi-drug resistance. 1 However, no long-term studies have examined the 
evolutionary history of MRSP’s resistance to antibiotics.  
Objective: The research project sought to phenotypically characterize historical MRSP 
environmental and canine isolates collected from The Ohio State University Veterinary 
Medical Center from 2007 to 2013.  
Results: Linear regression analysis showed that MRSP resistance increased significantly, 
by approximately one new class of antibiotic every 5 years, in environmental isolates 
pooled across all hospital locations. MRSP resistance did not increase significantly over 
time for canine isolates.  
Conclusions: MRSP appears to have increased its resistance to different classes of 
antimicrobial drugs over the past 6 years, suggesting that MRSP is continuing to acquire 
novel genetic components and become even more pathogenic. Researchers now need to 
focus on preventive measures that will deter or slow this process. 
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Literature Review 
Introduction 
The following literature review summarizes the background relevant to the 
primary objective of the reported study, which is to determine if Staphylococcus 
pseudintermedius strains circulating in The Ohio State University Veterinary Medical 
Center (OSU-VMC) have increased resistance to different classes of antibiotics from 
2007 to 2013. First, the Staphylococcus genus is described as a component of normal 
human and animal flora to show how it becomes an opportunistic pathogen. Then, the 
historical use of antibiotics is introduced to illustrate how the two primary methicillin-
resistant Staphylococcus species of interest, methicillin resistant S. aureus (MRSA) and 
methicillin resistant S. pseudintermedius (MRSP), emerged. Of the two, MRSA will be 
considered first in light of its relationship to MRSP. Then, MRSP will be introduced as 
the primary species of interest due to its ability to serve as a reservoir of resistant genes 
for MRSA. Next, the mechanisms by which MRSP has acquired antibiotic resistance will 
be discussed, to illustrate the ease with which MRSP could transmit its resistant genes to 
MRSA. Finally, the review will conclude with an outline of the aims of the experiment. 
Staphylococcus Genus  
 Staphylococci are gram-positive, facultative anaerobic, catalase positive, non-
motile bacteria that appear as round clusters when viewed underneath a microscope. 2 
Staphylococcus bacteria make up both human and animal flora by inhabiting carriage 
sites that include skin and mucosa membranes. 2 In canines, S. pseudintermedius is the 
dominant Staphylococcus species that asymptomatically inhabits 46 to 92% of healthy 
canines’ skin and mucosa. 3 In humans, S. aureus is the dominant Staphylococcus species 
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that asymptomatically inhabits a third of the human population. 4 Importantly, while S. 
pseudintermedius infrequently colonizes human skin and mucosa, S. aureus colonizes 
about 10% of healthy canines. 4 
 While Staphylococcus pathogens are normal inhabitants of animal and human 
skin and mucosa, they become opportunistic pathogens whenever the host immune 
response is compromised. 5 The genus is comprised of forty opportunistic pathogen 
species that vary in clinical importance. 2 To separate the genus into groups, 
staphylococci species are categorized as either coagulase positive or coagulase negative 
based on their ability to produce the coagulase enzyme. 2 The coagulase enzyme allows 
the bacterium to convert fibrinogen to fibrin, which allows blood clot formation. 2 
Coagulase positive staphylococci can evade certain host immune responses because the 
clot surrounds the bacteria and renders it invisible to the host system. 2 Of the coagulase 
positive staphylococci, S. aureus and S. pseudintermedius are the most clinically relevant 
pathogens for humans and animals because they naturally colonize a large percentage of 
these populations through carriage sites.  
 Furthermore, the Staphylococcus genus is known for its ability to acquire 
resistance to antibiotics. 5 The emergence of methicillin resistant S. aureus (MRSA) and 
methicillin resistant S. pseudintermedius (MRSP) has resulted in significant problems for 
human and veterinary medicine. 5 
Emergence of Antibiotic Resistance  
The first major widespread antibiotic, penicillin, has an intimate relationship with 
staphylococci because it led to the discovery of this genus’ resilience. 6 Penicillin was 
used as a primary treatment option for staph infections and its widespread use led to the 
	 6	
first penicillin resistant S. aureus strain being isolated within one year of its use. 6 It only 
took an additional ten years for penicillin resistant S. aureus clones to spread worldwide. 
6 When penicillin was no longer a viable treatment option, methicillin became the first 
line of treatment for staph infections. 7 However, in a fashion similar to penicillin 
resistance, methicillin resistant S. aureus (MRSA) strains quickly emerged.   
MRSA. S. aureus developed methicillin resistance through the acquisition of an 
alternative penicillin binding protein (PBP2a), which lowered the bacteria’s rapport for 
methicillin and all other beta-lactam antibiotics. 7 The resistant determining protein 
PBP2a is harbored on the staphylococcal cassette chromosome (SCCmec). 7 The 
significance of this mobile genetic element is that it has allowed the proliferation of eight 
distinct SCCmec types circulating among the MRSA strains. 7 These SCCmec types 
include insertion sequences, which allow for the integration of plasmids and permit the 
bacteria to evolve multi-drug resistance. 7 Instead of all strains being descended from a 
prototypic S. aureus strain with one introduction of SCCmec, modern MRSA strains are 
thought to represent independent procurements of SCCmec. 8  
MRSA infection can result in different types of clinical manifestations. 8 MRSA 
has the ability to attack large surgical wounds as well as small puncture wounds made by 
IVS or catheters, making it the most common cause of infections in hospital patients. 8 
Additionally, MRSA can cause both superficial and deep skin infections that result in 
boils, styes, or more serious types of invasive infections like bacteremia. 8  
By the mid-1970s, MRSA had spread to many, if not all, hospitals across the 
United States.9 MRSA isolates increased from 2.1% in 1975 to 35% in 1991. 10 By 2005, 
the CDC estimated 94,360 invasive MRSA infections occurred in the United States. 9 
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MRSA cases were not only spreading through hospitals via hospital-acquired MRSA but 
also through the community via community associated MRSA (CA-MRSA). 9 In 1999, 
four deaths caused by CA-MRSA in otherwise healthy children were reported. 11 While 
researchers are interested in CA-MRSA because of its ability to cause severe, aggressive 
diseases, the distinction between HA-MRSA and CA-MRSA is somewhat blurred as CA-
MRSA strains have been returning to hospital settings. 12  
Coinciding with the increase in MRSA infections in humans, the number of 
MRSA infections in canines has also increased over the past 10 years.4 While S. 
pseudintermedius is the primary staphylococci species found colonizing canines, S. 
aureus is isolated in about 10% of canines.4 Although MRSA colonization occurs in less 
than 1% of canines, several reports have established a rising number of canine MRSA 
infections resulting from open wounds and post-operative infections.4 MRSA infections 
in canines share similar clinical manifestations as those in humans, including dermatitis 
and pyoderma.4 
Because of the rising prevalence of MRSA infections in veterinary settings, 
concerns have arisen that MRSA’s similarity and relatedness to MRSP may permit the 
species to horizontally transfer resistance factors.1 Staphylococcal species have been 
generally assumed to form a gene pool from which all of the species can exchange 
mobile gene elements. 13 Because MRSP and MRSA share a common environment in the 
veterinary field, the two species could potentially transfer genetic elements to give rise to 
either a MRSP or MRSA clone that poses an even higher threat to human and veterinary 
health.  
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MRSP. Over the past decade, S. pseudintermedius, a bacteria considered part of 
the normal flora in dogs, has emerged as an opportunistic pathogen in the canine world. 1 
This pathogen poses a serious threat to canine health because it carries a large assortment 
of pathogenicity and virulence genes, which allow it to persist in adverse environments 
and to be capable of developing multi-drug resistance. 1 By asymptomatically inhabiting 
the nostrils, mouths, and anuses of healthy companion animals, S. pseudintermedius has 
evolved biological weapons to use against the animals whenever their immune systems’ 
ability to fight foreign bacteria is weakened. 1 For these reasons, S. pseudintermedius has 
become a significant pathogen responsible for causing severe veterinary hospital acquired 
infections.  
At some point in the recent past, S. pseudintermedius transitioned from being a 
susceptible bacterium, which was a part of canines’ normal flora, to being a 
microorganism resistant to beta-lactam antibiotics and additional classes of antibiotics.1 
MRSP isolates have increased from 5% to 30% of isolates collected in the United States 
from 2001 to 2007. 14 
Similar to MRSA, methicillin resistance in S. pseudintermedius is attributed to the 
mecA gene. 15 Two new staphylococcal cassette chromosome mec (SCCmec) elements, 
SCCmec II-III and VII, were detected in MRSP isolates, and represent two more 
reservoirs that can harbor the mecA gene and aid in the transfer of methicillin resistance 
to other staphylococcal species. 15 SCCmec II-III, SCCmec V and SCCmec VII-241 are 
all present in MRSP isolates. 13 SCCmec VII-241 is a novel element in MRSP isolates 
and is not related to any SCCmec elements found in S. aureus. 13 SCCmec II-III is a 
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hybrid of SCCmec II from S. epidermidis and of SCCmec III from S. aureus. 13 SCCmec 
V is homologous to the element in S. aureus. 13 
In addition to resistance to methicillin, high percentages of MRSP isolates 
collected from Europe and North America were found to be resistant to different classes 
of antibiotics. 13 In addition to mec-A mediated beta-lactam resistance, isolates were also 
found to be resistant to trimethoprim (90.3%), gentamicin/kanamycin (88.3%), 
streptomycin (90.3%), macrolides/lincosamides (89.3%), fluoroquinolone (87.4%), 
tetracyclin (69.9%), chloramphenicol (57.3%), and rifampicin (1.9%). 13 
Multi-drug resistant MRSP poses a serious threat to veterinary hospitals because 
all patients and personnel are at risk of carrying and transmitting the pathogen.1 Close 
contact between patients, patient owners, employees, and the environment increases the 
likelihood of cross-contamination and transmission.1 This contamination and continuous 
dissemination of MRSP increases the likelihood it will infect those it comes into contact 
with.1 With the increased prevalence of MRSP in veterinary hospitals also comes 
increased contact with antibiotics. Bacteria must be able to adapt to changing 
environments to survive; in the case of S. pseudintermedius, this adaptation includes its 
ability to adapt to antibiotics.1  
S. pseudintermedius contains numerous mobile genetic elements, including 
insertion elements, transposons, and an integrated plasmid and is, therefore, a bacterium 
that is capable of gaining and transferring DNA. 16 One study compared the changing 
numbers of S. pseudintermedius isolates resistant to antimicrobial drugs to the use of 
those specific antimicrobial drugs over the same time period in a veterinary clinic and 
found a pattern of resistance that reflected drug usage. 17 This study suggests that human 
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use of antimicrobial drugs poses a selective pressure on the bacteria that causes an 
increase in resistance that is specific to the drugs used. 17 
Data reflecting the rapid proliferation of a multi-drug resistant MRSP strain 
throughout Europe within a short time period highlights the need to better understand S. 
pseudintermedius’ evolution and acquirement of resistant genes, if we hope to limit its 
spread. 18 Prudent use of antimicrobial drugs in the veterinary setting is crucial in 
controlling the dissemination of more successful and more resistant clones.  
Transmission of Antibiotic Resistance  
Antibiotic drug use causes evolution of bacteria via the mechanism of natural 
selection; therefore, antibiotic resistance is an outcome of the selection for resistant 
bacteria. 19 Antibiotic resistance can be either natural or acquired, the latter being a 
consequence of the selective pressure exerted by antimicrobial drugs. 19 A bacterium can 
acquire resistance by mutations or the acquisition of extrachromosomal DNA. 19 Thus, 
mobile genetic elements, which can be transferred horizontally between bacteria, play a 
major role in acquired antibiotic resistance. 19 For example, bacteria have evolved 
accessory pieces of DNA that are separate from the chromosome itself. 20 These plasmids 
are independently duplicating genetic elements, which allow the bacteria to alter its 
genetic layout in the presence of new conditions. 20 Plasmids are the essential genetic 
components that allow bacteria to acquire and carry antibiotic resistance. 20 Bacteria can 
transfer plasmids via a process known as conjugation. 20 Acquiring antibiotic resistance 
via the transmission of extrachromosomal DNA including plasmids is known as 
horizontal transmission. Therefore, horizontal transmission is a common pathway 
through which S. pseudintermedius and S. aureus share resistance factors.  
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As mentioned earlier, S. pseudintermedius is increasingly suspected of serving as 
a reservoir of resistant genes for other Staphylococcus species. Additionally, due to our 
inability to determine directionality of transfer, S. pseudintermedius could also serve as a 
recipient of resistant genes from other Staphylococcus species. Whether serving as a 
reservoir or recipient, the possibility that S. pseudintermedius could acquire more 
resistance or that other Staphylococcal species could acquire more resistance should be a 
major concern for animal and human health. The reason that S. pseudintermedius poses 
the ability to serve as both a reservoir and recipient is because humans share close contact 
with their pet animals, which allows S. pseudintermedius to transfer to humans and S. 
aureus to transfer to animals. 21 Several studies have examined the ability of humans to 
carry S. pseudintermedius. One study found that the S. pseudintermedius strains occurring 
in dog-owners were found to be identical to the strains found in their dogs, which 
suggests a possible transfer of those bacterial strains between dog and human. 21 
Therefore, S. pseudintermedius and S. aureus can interact both on dogs who are carriers 
and humans who are carriers. While the studies do not suggest a direction of transfer or 
mode of transmission, bacteria carrying resistance genes can transfer them irrespective of 
directionality. In conclusion, because S. pseudintermedius harbors genes and plasmids 
related to those of S. aureus, there is a risk of genetic exchange between these 
staphylococcal species.   
Aims  
Thus, given time and exposure to antibiotics, MRSP has been postulated to be 
increasing its resistance to antibiotics.1 However, no long-term studies have directly 
examined the evolutionary history of MRSP’s resistance to antibiotics. Therefore, the 
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objective of the proposed research project is to phenotypically characterize historical 
MRSP isolates from the environment and from canines that were collected at OSU-VMC 
from 2007 to 2013. The phenotypic analysis will allow us to determine if the strains 
circulating in the OSU-VMC have increased their resistance over the years. The central 
hypothesis is that MRSP has been accumulating antibiotic resistance to an increasingly 
large number of classes of antimicrobial drugs. This research will also contribute to the 
larger objective of understanding the epidemiology of MRSP, with an end goal of 
controlling the dissemination and maintenance of this emerging nosocomial pathogen in 
veterinary hospitals. 
Materials and methods 
Source of Isolates 
A total of 211 MRSP isolates were collected at OSU-VMC between 2007-2013 
through active and passive surveillance. Isolates came from both the environment (130 
isolates) and from incoming canine patients (81 isolates). From November 2007 to 
October 2008, samplings of canines and the environment were conducted once every 
month. From November 2009 to November 2013, samplings of the environment were 
conducted once every 3 months. 
Specific services that were targeted for the environmental sampling were 
community practice (examination room and treatment area), dermatology (treatment 
room and wards), intensive care unit, surgery (pre-surgery room, anesthesia room, and 
surgery suites and wards), and rehabilitation. Within each hospital service, specific 
surfaces were chosen based on amount of contact during routine daily activities. High-
contact surfaces were chosen as they had a higher likelihood of being contaminated. 
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Furthermore, a surface was labeled as a human contact surface if it was regularly touched 
by humans throughout the day and generally out of reach from direct contact with 
animals (e.g., computers). In comparison, a surface was labeled as an animal contact 
surface if it was primarily in direct contact with multiple animals (e.g., cages). Table 1 
(see next page) outlines which environmental surfaces were considered human or animal 
contact surfaces. 
During only the first year, in addition to the environmental samples, incoming 
dogs admitted to the hospital were sampled upon their arrival if they had not been in the 
hospital in the past 6 months. For each enrolled canine, sterile pre-moistened cotton 
swabs were used to collect samples from the nasal cavity, ear canals, external surface of 
the perianal area, and any skin lesions (if present).  
S. pseudintermedius samples were identified using standard microbiological and 
biochemical tests. MRSP isolation and identification began with samples being incubated 
at 35°C in pre-enrichment media for 24 hours and then streaked onto mannitol salt agar 
(BD BBL™Mannitol Salt Agar, Dickinson and Company) with 2 μg/mL of oxacillin. 
After 24 to 48 hours, 1 to 3 colonies per sample were selected and streaked onto 
trypticase soy agar with 5% sheep blood (Remel®, Blood Agar [trypticase soy agar, TSA, 
with 5% sheep blood], Lenexa, KS). Identification of S. pseudintermedius was performed 
by standard colony morphology and biochemical tests reactions that included mannitol 
fermentation, gram stain, catalase, tube coagulase, anillin fermentation, Polymyxin B 
susceptibility, acetoin production (Vogues-Proskauer test) and latex agglutination (Sure-
Vue® Color Staph ID, Biokit USA, Inc., Lexington, MA). 22 Phenotypic MRSP 
confirmation was performed by growth on Oxacillin Screen Agar® (OSA) plates 
	 14	
containing 6 μg/mL of oxacillin supplemented with NaCl (BD BBLTM, Becton 
Dickinson and Company) following the Clinical Laboratory Standards Institute (CLSI) 
protocols.23   
Antimicrobial Susceptibility Testing 
Antimicrobial susceptibility profiles of 130 environmental isolates and 81 canine isolates 
were determined by testing against 16 antibiotics frequently used in both the veterinary 
and human field of medicine, using the Kirby Bauer Disk Diffusion technique established 
by CLSI. 23 Antimicrobials included were: amikacin 30 μg, ampicillin 10 μg, amoxicillin 
with clavulanic acid 20/10 μg, cefpodoxime 10 μg, cephalothin 30 μg, chloramphenicol 
30 μg, ciprofloxacin 2 μg, clindamycin 2 μg, doxycycline 30 μg, enrofloxacin 5μg, 
erythromycin 15 μg, gentamicin 1 μg, oxacillin 1 μg, sulfamethoxazole with 
trimethoprim 1.25/23.75 μg, and tetracycline 30 μg. Vancomycin resistance was tested 
using Vancomycin Screen Agar plates (6 mg/L) (BD BBL™ Vancomycin Screen Agar, 
Dickinson and Company, Sparks, USA). Inducible Clindamycin resistance was tested 
using the D-test. 24 Antimicrobial susceptibility patterns were grouped in profiles based 
on their pattern similarity, and later classified as multidrug resistant (MDR) if they were 
resistant to 3 or more classes of antimicrobials (including beta-lactams). For quality 
control purposes, six strains were included in each round: S. aureus (ATCC 43300), S. 
aureus (ATCC 29213), S. aureus (ATCC 25923), Enterococcus faecalis (ATCC 23212), 
Escherichia coli (ATCC 25922), and Pseudomonas aeruginosa (ATCC 27853). All 
samples were processed in the Diagnostic and Research Laboratory of Infectious 
Diseases (DRLID), which is a Bio Safety Level 2 laboratory (rooms 367, 371 and 375) 
located at the Veterinary Medicine Academic Building (VMAB) of OSU.  
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Table 1: Human and Canine Contact Surfaces Sampled with Electrostatic Cloths (✖) or 
Sterile Swabs (★) by Service at the Small Animal Hospital in the Ohio State University 
Veterinary Medical Center during Surveillance.  
Hospital service Human contact surface Animal contact surface 
Community practice Doors ✖ 
Computers ✖a,b 
Otoscope ★ 
Exam tables ✖a 
Floor (exam) ✖a 
Muzzles ★ 
Dermatology Doors (ward) ✖ 
Exam lights ✖ 
Fax/phone ★ 
Computer ★b 
Microscope ★ 
Otoscope ★ 
Paper towel dispenser ★a 
Alcohol-gel dispensers ★a 
Cages (ward) ✖ 
Floors (exam) ✖ 
Muzzles (ward) ★ 
Water bowels (ward) ★ 
Intensive care unit Doors ✖ 
IV pumps ★ 
Computer ★a,b  
Laptop ★ 
Cages (2) ✖ 
Muzzles ★ 
Water bowls ★ 
Surgery Clippers ★ 
Doors ✖ 
Drawer handles ✖ 
Exam lights ✖a 
Light switches ✖a 
Table knobs ✖a 
Cages ✖ 
Exam tables ✖ 
Muzzles (ward) ★ 
Oxygen monitors ★ 
Warming pads ✖c 
Water bowls ★ 
General 
 
NA  
 
Carts/gurney ✖ (3) 
 
Rehabilitation Doors ✖ Walls of the pool ✖ 
Floaties ✖ 
Mats ✖ 
Balls ✖ 
Slings ✖ 
Muzzles ★ 
Laser ★ 
aSamples collected as a pool within the same service. bIncluded keyboard and mouse. cMultiple warming pads located in the same room were sampled as a pool.  IV, intravenous; NA, not applicable.  
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Statistical Analysis  
All results were organized in an Excel spreadsheet and basic frequencies and 
distributions were generated. Boxplots were used to compare distributions of mean 
number of resistant classes between services (community practice, dermatology, general, 
intensive care unit, rehabilitation, and surgery). A one-way ANOVA model was used to 
compare the mean number of resistant classes for each of the six locations. Simple linear 
regression models were used to fit basic time series models, using months as the 
independent variable and number of resistant classes as the dependent variable. Multiple 
regression models were considered to incorporate the possible impact of location and 
time on the prediction of resistance. Regression coefficients were obtained using the 
statistical software Minitab statistical software (Version 16.2.4). Relationships were 
considered statistically significant when their P-value (two-sided) was ≤ 0.05.   
Results 
Phenotypic characterization of MRSP environmental isolates 
A total of 130 MRSP environmental isolates that were collected from December 
2007 to November 2013 at OSU-VTH were phenotypically characterized. As expected, 
all of the MRSP environmental isolates were resistant to antibiotic class beta-lactams. 
The vast majority of the MRSP environmental isolates (94%) were multi-drug resistant or 
resistant to 3 or more classes of antibiotics. Lincosamide (90%), potentiated sulfonamide 
(81%), macrolides (78%), and quinolone (78%) were the most frequent classes of 
antibiotics to which MRSP environmental isolates were resistant. Around half of the 
MRSP environmental isolates (52% and 41%) were resistant to tetracycline and 
aminoglycoside, respectively. All MRSP environmental isolates except for 8 were 
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susceptible to antibiotic class phenicol (94%) and all of the MRSP environmental isolates 
were susceptible to antibiotic class glycopeptides (100%). The most frequent class profile 
of resistance (28%) included beta-lactams, quinolone, macrolides, lincosamide, 
aminoglycoside, and potentiated sulfonamide (see Table 1). All MRSP environmental 
isolates were susceptible to amikacin and vancomycin (see Table 2).  
Antibiotic resistance by hospital surface for MRSP environmental isolates 
The distributions of the number of antibiotic classes to which MRSP 
environmental isolates were resistant across different hospital surfaces were inspected 
using box and whisker plots (see Figure 1). The mean number of resistant antibiotic 
classes did not vary significantly by location (F= 0.64, P= 0.671), suggesting that 
antibiotic resistance was not a function of the specific hospital surface that was sampled. 
Antibiotic resistance over time for MRSP environmental isolates 
MRSP environmental isolates increased their antibiotic resistance over time, as 
reflected in a significant positive relationship between the number of resistant antibiotic 
classes and the month when samples were obtained (F= 9.05, P= 0.003) (see Figure 2). 
The number of classes to which the MSRP environmental isolates were resistant 
increased by roughly 1 class every 4 to 5 years. To determine if a non-linear model would 
account for more of the variance in antibiotic resistance, locally weighted scatterplot 
smoothing was used to obtain an alternative model that shows the best possible fit to the 
data (Figure 3). The resulting model showed that antibiotic resistance increased linearly 
after the first 10 months of data collection, suggesting that the linear regression model 
provides an adequate fit to the data. 
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 Next, the possible impact of hospital service on the relationship of antibiotic 
resistance to time of sampling was explored. For dermatology only, the number of 
resistant classes of antibiotics was positively related to the month when sampling 
occurred (F= 6.08, P= 0.018) (see Figure 4). The relationship of antibiotic resistance to 
time of sampling was not significant in any of the other locations; this may be because of 
the small number of samples available for most specific locations.   
Antibiotic resistance by type of contact surface (human versus animal) for MRSP 
environmental isolates 
The number of antibiotic classes showing MRSP resistance did not differ 
significantly between human and animal contact surfaces. When controlling for the 
month when sampling occurred, the mean number of resistant antibiotic classes did not 
vary significantly across human and animal contact surfaces (F= 0.319, P= 0.573). 
Phenotypic characterization of MRSP canine isolates  
A total of 81 MRSP canine isolates that were collected from November 2007 to 
October 2008 at OSU-VTH were phenotypically characterized. The vast majority of 
canine isolates (91.4%) were multi-drug resistant. As expected, all of the canine isolates 
were resistant to antibiotic class beta-lactams. Lincosamide (99%), macrolides (81%), 
potentiated sulfonamide (64%), and quinolone (63%) were the most frequent classes of 
antibiotics to which MRSP canine isolates were resistant. A little under half of the 
isolates (42% and 33%) were resistant to aminoglycoside and tetracycline, respectively. 
All of the MRSP canine isolates except for one were susceptible to phenicol, and all of 
the MRSP canine isolates were susceptible to glycopeptides (see Table 3). All of the 
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isolates were susceptible to vancomycin, and 98% of the isolates were susceptible to 
amikacin and chloramphenicol (see Table 2).   
Antibiotic resistance over time for MRSP canine isolates  
The number of antibiotic classes to which MRSP canine isolates were resistant 
did not increase significantly as a function of when sampling occurred (F= 2.19, P= 
0.143)  (see Figure 5). The number of resistant antibiotic classes across different 
anatomical locations-ears, lesion, nose, and perianal-were inspected with box and 
whisker plots (see Figure 6). The mean number of resistant antibiotic classes did not vary 
significantly across anatomical locations (F= 0.64, P= 0.671).  
Discussion  
While MRSP infections continue to rise in prevalence and an increasing number 
of MRSP strains are reported to be multi-drug resistant, no long-term studies have 
tracked changes in MRSP’s resistance to antibiotics over time to determine whether 
MRSP is indeed acquiring resistance to additional classes of antibiotics. Therefore, this 
study sought to phenotypically characterize historical MRSP canine and environmental 
isolates that were collected from OSU-VTH over the span of six years to examine 
MRSP’s antibiotic resistance during that period. The study’s objective was accomplished, 
as 211 isolates were phenotypically characterized and changes in susceptibility patterns 
were observed. The importance of phenotypically characterizing these MRSP isolates 
stems from the risk MRSP poses to public health because of its unique relationship with 
MRSA.  
First, the results indicated that both environmental and canine MRSP isolates 
show high rates of antimicrobial resistance. Ninety four percent of MRSP environmental 
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isolates and 91% of MRSP canine isolates were multi-drug resistant. This high rate of 
antimicrobial resistance is reflected in a similar multi-center study conducted by Perreten 
et al. 13 They found MRSP isolates to be resistant to trimethoprim (90.3%), gentamicin 
(88.3%), macrolides and/or lincosamide (89.3%), tetracycline (69.9%), and 
chloramphenicol (57.3%). 13 Similarly, our study found MRSP environmental and canine 
isolates to be resistant to trimethoprim (81/64%), gentamicin (41/42%), macrolides 
(78/80%), lincosamide (78/78%), tetracycline (51/33%), and chloramphenicol (6/1%) 
respectively (see Table 2). Although our MRSP isolates showed slightly lower 
proportions of resistance than those reported by Perreten et al., both studies found MRSP 
isolates to have high rates of antimicrobial resistance and, more importantly, resistance to 
multiple antimicrobials regularly used in veterinary medicine. 13 Furthermore, no other 
studies exist to suggest that MRSP has low resistance to antimicrobials. Therefore, the 
current results highlight a serious problem that can potentially impact animal health when 
trying to treat MRSP infections, as clinically available treatment options are extremely 
limited.  
Second, the results indicated that the distribution of antibiotic resistance across 
hospital services (community practice, dermatology, ICU, surgery, and rehabilitation) 
and between type of contact surface (animal versus human) for MRSP environmental and 
canine isolates did not vary significantly. No studies exist showing that the distribution of 
antibiotic resistance for MRSP isolates vary significantly between type of contact surface 
and across services. However, prior studies have illustrated the ability of MRSA to 
contaminate both human and animal contact surfaces, consistent with the current findings 
involving MRSP. 25 Our finding, paired with van Balen et al., 25 highlights the concern 
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that MRSA and MRSP potentially share three common environments- human carriage 
sites, canine carriage sites, and environmental surfaces contacted frequently by animals 
and/or humans. In any of these environments, MRSA and MRSP could potentially share 
resistance genes. 
Third, the results suggest that MRSP environmental isolates are becoming 
resistant to one new antibiotic class approximately every 5 years. Although we found that 
a large proportion of MRSP isolates are resistant to many antimicrobials frequently used 
in veterinary medicine, the increase in resistant classes over the study period indicates 
that MRSP environmental isolates are continuing to acquire resistance. No long-term 
studies have tracked changes in MRSP’s resistance to antibiotic classes over time. 
Therefore, it is quite difficult to compare our results due to the lack of publications. In 
any case, this finding adds to the pressure on personnel within the veterinary field to 
create a system that slows the spread of resistance in this type of pathogen. If this trend of 
becoming resistant to more and more classes of antibiotics continues, then MRSP 
infections may become incurable, as no treatment options will remain. 
For these reasons, veterinarians need to be aware of the effectiveness of particular 
antibiotics when combating MRSP infections. The continued use of ineffective 
antibiotics could be potentially harmful to their patients, and the overuse of effective 
antibiotics could hasten the process by which MRSP isolates gain resistance. As a result, 
veterinarians face a dilemma: Do they introduce new antibiotics into the system that will 
likely result in the bacteria becoming resistant to them or continue to rely upon antibiotics 
that will continue to become less effective as resistance spreads? Additionally, the 
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process of developing a new antibiotic is a long, resource intensive, and complex process 
that many pharmaceutical companies are not willing to undertake. 6 
Therefore, veterinarians need to combine a rigorous antimicrobial drug use policy 
with a stringent cleaning procedure of the environment and hygiene protocol for 
veterinary hospital personnel if they want to limit the spread of antibiotic resistance 
among MRSP isolates. The drug use policy needs to require MRSP infections to be 
phenotypically characterized before a specific antibiotic is chosen, and canines need to be 
followed closely over the course of treatment to ensure minimal spread of the bacteria to 
the environment, other dogs, and humans. Prudent use of antimicrobials combined with 
cleaning and hygiene protocols are the primary methods for controlling the spread of 
resistant bacteria. 
One of the primary limitations of the study is that the design is 
correlational/observational and not experimental, which precludes any definitive 
conclusions about causation. Nevertheless, the results show that MRSP antibiotic 
resistance is increasing, even though they cannot serve as a basis for identifying specific 
mechanisms. Second, the number of MRSP canine isolates was relatively small because 
they were collected over a shorter amount of time (1 year) as compared to the MRSP 
environmental isolates (6 years). This limitation makes the power of statistical analysis 
lower for the MRSP canine isolates than that for the analysis of the MRSP environmental 
isolates. However, high antimicrobial resistance was clearly demonstrated in both types 
of isolates. Lastly, the generalizability of our results to other hospitals within the US is 
uncertain, as all of our data were collected from a single teaching hospital. However, the 
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findings of antimicrobial resistance are consistent with those reported from other 
hospitals.  
In conclusion, this study has demonstrated the importance of tracking the 
evolution of a bacterium that poses serious issues to veterinary medicine, and indirectly, 
to public health. For animal health, if MRSP continues to acquire resistance, MRSP 
infections will become ever more challenging to prevent and treat. For public health, if 
MRSP and MRSA potentially transfer antimicrobial resistant genes between one another 
because they are both present in multiple common environments, then MRSA might also 
become more resistant and difficult to treat in human and canine cases. Our findings 
highlight the importance of antimicrobial stewardship, cleaning, and hygiene protocols 
and continuing to perform surveillance of MRSP isolates.  
This thesis represents the retrospective component of a much larger study. The 
results of my study will be compared to current isolates being collected at OSU-VMC. 
The larger research project will be a comprehensive study, with both prospective and 
retrospective components, that analyzes MRSP in a veterinary teaching hospital. A 
second team member will be performing the analysis of the current MRSP isolates, and 
the studies will be combined prior to publication. Molecular characterization will be 
performed as well. The long-term goal is to increase our knowledge of the changing 
epidemiology of MRSP and thereby foster the development of an infectious disease 
control plan that will decrease the dissemination of MRSP throughout the OSU-VMC, 
and that can be shared with other veterinary hospitals worldwide.  
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Appendix  
 
Table 1: MRSP environmental isolates categorized into groups by antibiotic class profile. 
The number of isolates (frequency) and percentage of each profile is listed.  
 
Antibiotic Class Profile Number of Antibiotics 
Classes 
Frequency Percent 
B, Q, M, A, L, S 6 37 28.5 
B, Q, M, L, T, S 6 36 27.7 
B, Q, M, L, S 5 14 10.8 
B, Q, L, T 4 7 5.4 
B, Q, M, A, L, T, S, P 8 4 3.1 
B, L, T 3 4 3.1 
B 1 4 3.1 
B, Q, M, L, T, S, P 7 3 2.3 
B, A 2 3 2.3 
B, M, L, T, S 5 2 1.5 
B, M, L, T 4 2 1.5 
B, M, A, L 4 2 1.5 
B, L, S 3 2 1.5 
B, A, T, S 4 2 1.5 
B, A, T 3 2 1.5 
B, A, L, T, S 5 2 1.5 
B, T, S 3 1 0.8 
B, T 2 1 0.8 
B, M, L, T, S, P 6 1 0.8 
B, M, A, L, T, S 6 1 0.8 
  
B=Beta-lactams, Q=Quinolone, M=Macrolides, A=Aminoglycoside, L=Lincosamide, S=Potentiated 
Sulfonamide, T=Tetracycline, P=Phenicol  
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Table 2: Description of the relative effectiveness of each antibiotic against both MRSP 
environmental (VTH) and canine (CAN) isolates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibiotic Effectiveness Against Canine and VTH MRSP Isolates 
Antibiotic Class Antibiotic Abr. 
Resistant (%) Intermediate (%) Susceptible (%) 
Can VTH Can VTH Can VTH 
Aminoglycoside Gentamicin GEN 34 (42%) 53 (41%) 7 (9%) 19 (15%) 40 (49%) 58 (45%) 
  Amikacin AMK 1 (1%) 0 (0%) 1 (1%) 0 (0%) 79 (98%) 130 (100%) 
Beta-Lactams Ampicillin AMP 81 (100%) 130 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
 
Amoxicillin with 
Clavunate AMC 39 (48%) 62 (48%) 0 (0%) 0 (0%) 42 (52%) 68 (52%) 
 
Oxacillin OXA 57 (70%) 101 (78%) 6 (7%) 1 (1%) 18 (22%) 28 (22%) 
 
Cephalotin CEP 19 (23%) 43 (33%) 9 (11%) 12 (9%) 53 (65%) 75 (58%) 
 
Cefpodoxime CPD 66 (81%) 111 (85%) 
12 
(15%) 9 (7%) 3 (4%) 10 (8%) 
Glycopeptides Vancomycin VAN 0 (0%) 0 (0%) 0 (0%) 0 (0%) 81 (100%) 130 (100%) 
Lincosamide Clindamycin CLI 63  (78%) 102 (78%) 2 (2%) 0 (0%) 16 (20%) 28 (22%) 
Macrolides Erythromycin ERY 65 (80%) 102 (78%) 0 (0%) 0 (0%) 16 (20%) 28 (22%) 
Phenicol Chloramphenicol CHL 1 (1%) 8 (6%) 1 (1%) 0 (0%) 79 (98%) 122 (94%) 
Quinolone Enrofloxacin ENO 49 (60%) 101 (78%) 2 (2%) 6 (5%) 30 (37%) 23 (18%) 
  Ciprofloxacin CIP 51 (63%)  101 (78%) 2 (2%) 6 (5%) 28 (35%) 23 (18%) 
Tetracycline Tetracycline TET 27 (33%) 66 (51%) 1 (1%) 0 (0%) 53 (65%) 64 (49%) 
 
Doxycycline DOX  27 (33%) 66 (51%) 0 (0%) 0 (0%) 54 (67%) 64 (49%) 
Potentiated 
Sulfonamide  
Sulfamethoxazole 
with Trimethoprim SXT 52 (64%) 105 (81%) 1 (1%) 7 (5%) 28 (35%) 18 (14%) 
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Table 3: MRSP canine isolates categorized into groups by antibiotic class profile. The 
number of isolates (frequency) and percentage of each profile is listed.  
 
Antibiotic Class Profile Number of Antibiotic 
Classes 
Frequency Percent 
B, A, L, M, Q, S 6 25 30.9 
B, L, M, Q, S 5 10 12.3 
B, L, M 3 8 9.9 
B, L, M, T 4 7 8.6 
B, L 2 7 8.6 
B, L, M, Q, T, S 6 6 7.4 
B, L, T 3 5 6.2 
B, A, L, M, Q, T, S 7 4 4.9 
B, A, L, Q, S 5 3 3.7 
B, L, M, T, S 5 2 2.5 
B, L, Q 3 1 1.2 
B, L, M, P, Q, T, S 7 1 1.2 
B, A, M, Q, T, S 6 1 1.2 
B, A, L, M, T 5 1 1.2 
 
B=Beta-lactams, Q=Quinolone, M=Macrolides, A=Aminoglycoside, L=Lincosamide, S=Potentiated 
Sulfonamide, T=Tetracycline, P=Phenicol  
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Figure 1: Box and whisker plot used to compare distribution of the number of classes of 
antibiotics that MRSP environmental isolates were resistant to by location.    
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Figure 2: Regression analysis of antibiotic classes versus months for MRSP 
environmental isolates. 
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Figure 3: Nonparametric regression for antibiotic classes versus months for MRSP 
environmental samples. 	
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Figure 4: Regression analysis for MRSP environmental isolates collected from 
dermatology. 	
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Figure 5: Regression analysis of antibiotic classes versus months for MRSP canine 
isolates.  
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Figure 6: Boxplot of antibiotic classes versus anatomical location for MRSP canine 
isolates.  
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